Brief: Bone Therapeutics End-March Net Cash At EUR 6.0 Mln

Biosenic SA

01/06/2022 06:12

June 1 (Reuters) - Bone Therapeutics SA  BOTHE.BR :
    * BONE THERAPEUTICS PROVIDES FIRST QUARTER 2022 BUSINESS
UPDATE
    * NET CASH AT END OF MARCH 2022 AMOUNTED TO EUR 6.0 MILLION
    * NET CASH BURN FOR FULL YEAR 2022 IS EXPECTED TO BE IN
RANGE OF
EUR 8-10 MILLION
    * ANTICIPATES HAVING SUFFICIENT CASH TO CARRY OUT ITS
BUSINESS
OBJECTIVES INTO Q1 2023
    * IN ONGOING PHASE IIB ALLOB CLINICAL STUDY IN DIFFICULT
TIBIAL
FRACTURES, BONE THERAPEUTICS EXPECTS TO REPORT TOPLINE RESULTS
AS SCHEDULED BY Q1 OF 2023
    * NEGOTIATIONS FOR ALLOB, WITH ONE OF BONE THERAPEUTICS'
CURRENT
CHINESE PARTNERS, FOR GLOBAL RIGHTS AGREEMENT ARE STILL ONGOING
BUT ARE TAKING LONGER THAN ORIGINALLY ANTICIPATED
    * ALLOB NEGOCIATIONS: POTENTIAL COMPLETION OF A FINAL
BINDING
AGREEMENT IS ANTICIPATED IN Q2 2022
    * BONE THERAPEUTICS AND MEDSENIC AIM TO REACH AN AGREEMENT
IN
COURSE OF Q2/Q3 2022

Source text for Eikon:  ID:nGNE9yLVtR 
Further company coverage:  BOTHE.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))